openPR Logo
Press release

Apixaban Market - Size, Share, Outlook, and Forecast till 2026

Apixaban Market - Size, Share, Outlook, and Forecast till 2026

Apixaban is an anticoagulant used to reduce blood clotting and risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is an oral factor Xa inhibitor and is sold under the trade name Eliquis. It was approved in Europe in 2012 and in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban was developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Increasing geriatric population and prevalence of atrial fibrillation in people over 80 years old are major factors that are expected to drive growth of apixaban market over the forecast period. Moreover, increasing incidences of deep vein thrombosis and pulmonary embolism is another factor boosting growth of apixaban market. Also, increasing investment in research and development activities in the pharmaceutical sector and launch of innovative oral anticoagulant drugs are fueling the market growth.

However, stringent regulations by governments and risk of side-effects and complications associated with the usage of oral anticoagulants is expected to hinder growth of the global apixaban market.

Key Developments in Apixaban Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the apixaban market. On March 6, 2017, Bristol-Myers Squibb and Pfizer announced that they will present new analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session.
Request for Sample Copy of Research Report:https://www.worldwidemarketreports.com/sample/196789
Bristol-Myers Squibb Company and Pfizer reported that they have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with Acute Coronary Syndrome (ACS) who were treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. The study was stopped at an early stage based on the recommendation of an independent Data Monitoring Committee (DMC).
Get Best Discount on Research Report:https://www.worldwidemarketreports.com/discount/196789
On December 5, 2017, Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the around seven million people in the U.S. in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.

Some of the major players in the global apixaban market include Pfizer, Medichem, Polpharma, Beijing Cooperate Pharmaceutical, Centaur Pharmaceutical, DEAFARMA, and Dipharma Francis among others.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

1001 4th Ave,
#3200
Seattle, WA 98154,
U.S

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Apixaban Market - Size, Share, Outlook, and Forecast till 2026 here

News-ID: 1212784 • Views: 230

More Releases for Pfizer

Pfizer Indian Offices in a BioBubble
Kolkata, December 2021 - “Our science holds the cure”, Pfizer believes. One of the leading World’s Premier Pharmaceutical and Biotech Corporation Company Pfizer delivers wellness, prevention, treatment, and cure to combat the most feared diseases. Pfizer appreciated and implemented this revolutionary idea of disinfection by Chemtex, going by the name of BioBubble. Pfizer, a research-based global biopharmaceutical company has taken steps to protect their high foot traffic points and potential hotspots
Global Pentostatin Market 2019 Scenario of Top Sellers: • Hospira (Pfizer),• …
The "Pentostatin market" study formulated by Up Market Research, presents a detailed analysis of the influential trends prevailing in this business sphere. This research report also offers definitive information concerning the commercialization of this vertical, market size, and revenue estimation of this industry. The study explicitly illustrates the competitive standing of key players over the projected timeline while incorporating their individual portfolios & geographical expansion. The Global Pentostatin market 2019
Migraine Drugs Market Research Exclusive Report 2019-2025 | Top Key Players Alle …
UpMarketResearch offers a latest published report on “Global Migraine Drugs Market Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 123 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Get Exclusive FREE Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/46396 Migraine Drugs Market research report delivers
Ticagrelor Market 2022 Outlook – by Pfizer, Amgen, Merck, Roche, GSK, Alexion, …
The report for Ticagrelor Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro
New Report On Migraine Drugs Market 2018 Global Analysis By Key Players – Alle …
Migraine Drugs Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. Get FREE Sample Report Before Buying @ https://www.upmarketresearch.com/home/requested_sample/5116 UpMarketResearch offers a latest published report on “Global Migraine Drugs Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage to clients through a detailed
Global Axitinib Market 2018 - Pfizer
Apex Market Reports, recently published a detailed market research study focused on the “Axitinib Market” across the global, regional and country level. The report provides 360° analysis of “Axitinib Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Axitinib on the basis of